1. Consort Diagram 600 pts with 644 eyes accessed for eligibility
86 pts with 130 eyes excluded
514 pts included in study each contributing 1 eye
44 bilateral pts with each eye group D or E
32 pts received extensive pre-enucleation treatment
2 pts died from chemo toxicity
3 pts received pre-enucleation chemo for less than one complete cycle
3 pts had non-tumor enucleation
2 pts abandoned treatment after tumor recurrence
1 atrophy w/o chemo
2 vitreous hemorrhage
174 D eyes
340 E eyes
3 plaque
6 PPV
1 stem cell
18 IAC
3 radio
Factors to consider: pathologic staging, time from diagnosis to enu, neoadjuvant chemo, adjuvant chemo
Dependent variable: mortality.
1 immunotherapy

2. Relationship between neoadjuvant chemo cycle and pathology for staged D&E Eyes
Low Risk Pathology (LRP): pT1 and pT2
High Risk Pathology (HRP): pT3 and pT4

3. Relationship between neoadjuvant chemo cycle and mortality
After Controlling for Adjuvant Chemo
(Kaplan Mier Survival Analysis)